- Home
- TNON vs CDT Comparison
TNON vs CDT Comparison
Compare TNON & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNON
- CDT
- Stock Information
- Founded
- TNON 2012
- CDT 2019
- Country
- TNON United States
- CDT United States
- Employees
- TNON N/A
- CDT N/A
- Industry
- TNON Medical Specialities
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- TNON Health Care
- CDT Health Care
- Exchange
- TNON Nasdaq
- CDT Nasdaq
- Market Cap
- TNON 6.7M
- CDT 7.1M
- IPO Year
- TNON 2022
- CDT N/A
- Fundamental
- Price
- TNON $1.79
- CDT $0.07
- Analyst Decision
- TNON Strong Buy
- CDT
- Analyst Count
- TNON 2
- CDT 0
- Target Price
- TNON $16.00
- CDT N/A
- AVG Volume (30 Days)
- TNON 153.6K
- CDT 101.0M
- Earning Date
- TNON 03-11-2025
- CDT 02-14-2025
- Dividend Yield
- TNON N/A
- CDT N/A
- EPS Growth
- TNON N/A
- CDT N/A
- EPS
- TNON N/A
- CDT N/A
- Revenue
- TNON $3,315,000.00
- CDT N/A
- Revenue This Year
- TNON $29.03
- CDT N/A
- Revenue Next Year
- TNON $100.29
- CDT N/A
- P/E Ratio
- TNON N/A
- CDT N/A
- Revenue Growth
- TNON 38.30
- CDT N/A
- 52 Week Low
- TNON $1.65
- CDT $0.05
- 52 Week High
- TNON $15.79
- CDT $3.92
- Technical
- Relative Strength Index (RSI)
- TNON 39.49
- CDT 45.83
- Support Level
- TNON $1.65
- CDT $0.08
- Resistance Level
- TNON $2.30
- CDT $0.18
- Average True Range (ATR)
- TNON 0.16
- CDT 0.02
- MACD
- TNON 0.01
- CDT 0.00
- Stochastic Oscillator
- TNON 21.57
- CDT 11.90
About TNON Tenon Medical Inc.
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities: 1) Primary SI Joint procedures, 2) Revision procedures of failed SI Joint implants, and 3) SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
About CDT Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.